JP5329731B2 - ルピンのペプチド抽出物およびそれを含有する医薬組成物、化粧品組成物または栄養組成物 - Google Patents
ルピンのペプチド抽出物およびそれを含有する医薬組成物、化粧品組成物または栄養組成物 Download PDFInfo
- Publication number
- JP5329731B2 JP5329731B2 JP2000611925A JP2000611925A JP5329731B2 JP 5329731 B2 JP5329731 B2 JP 5329731B2 JP 2000611925 A JP2000611925 A JP 2000611925A JP 2000611925 A JP2000611925 A JP 2000611925A JP 5329731 B2 JP5329731 B2 JP 5329731B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- extract
- lupine
- mmp
- collagenase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims description 87
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 71
- 241000219745 Lupinus Species 0.000 title claims description 51
- 239000000203 mixture Substances 0.000 title claims description 32
- 239000002537 cosmetic Substances 0.000 title claims description 11
- 235000016709 nutrition Nutrition 0.000 title 1
- 229960002424 collagenase Drugs 0.000 claims description 44
- 102000029816 Collagenase Human genes 0.000 claims description 34
- 108060005980 Collagenase Proteins 0.000 claims description 34
- 102000008186 Collagen Human genes 0.000 claims description 30
- 108010035532 Collagen Proteins 0.000 claims description 30
- 229920001436 collagen Polymers 0.000 claims description 30
- 229920000159 gelatin Polymers 0.000 claims description 23
- 239000008273 gelatin Substances 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 102000005741 Metalloproteases Human genes 0.000 claims description 13
- 108010006035 Metalloproteases Proteins 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 230000015556 catabolic process Effects 0.000 claims description 12
- 102000013382 Gelatinases Human genes 0.000 claims description 11
- 108010026132 Gelatinases Proteins 0.000 claims description 11
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 208000028990 Skin injury Diseases 0.000 claims description 7
- 230000032683 aging Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 102000016942 Elastin Human genes 0.000 claims description 3
- 108010014258 Elastin Proteins 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 229920002549 elastin Polymers 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 102000007547 Laminin Human genes 0.000 claims description 2
- 108010085895 Laminin Proteins 0.000 claims description 2
- 230000009931 harmful effect Effects 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 6
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 6
- 241000208125 Nicotiana Species 0.000 claims 1
- 208000019155 Radiation injury Diseases 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 71
- 230000000694 effects Effects 0.000 description 48
- 239000000047 product Substances 0.000 description 32
- 238000012360 testing method Methods 0.000 description 31
- 235000019441 ethanol Nutrition 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- 239000000835 fiber Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 15
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 14
- 239000011535 reaction buffer Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 8
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 8
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 8
- 101710108790 Stromelysin-1 Proteins 0.000 description 8
- 102100030416 Stromelysin-1 Human genes 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 244000068988 Glycine max Species 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 239000003068 molecular probe Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 108010072906 phosphoramidon Proteins 0.000 description 6
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 235000010215 titanium dioxide Nutrition 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 5
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 229940085605 saccharin sodium Drugs 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000011775 sodium fluoride Substances 0.000 description 5
- 235000013024 sodium fluoride Nutrition 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 4
- KGKQNDQDVZQTAG-UHFFFAOYSA-N 8-methylnonyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)(C)C KGKQNDQDVZQTAG-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 238000005498 polishing Methods 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 238000001061 Dunnett's test Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940086555 cyclomethicone Drugs 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 3
- 238000000556 factor analysis Methods 0.000 description 3
- 230000000855 fungicidal effect Effects 0.000 description 3
- 239000000417 fungicide Substances 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940100556 laureth-23 Drugs 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 239000004175 ponceau 4R Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 229960003500 triclosan Drugs 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 229920002292 Nylon 6 Polymers 0.000 description 2
- 244000025272 Persea americana Species 0.000 description 2
- 235000008673 Persea americana Nutrition 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 244000044822 Simmondsia californica Species 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 244000046101 Sophora japonica Species 0.000 description 2
- 235000010586 Sophora japonica Nutrition 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 229960003993 chlorphenesin Drugs 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940091249 fluoride supplement Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 2
- 230000000477 gelanolytic effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229940078812 myristyl myristate Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- 240000000894 Lupinus albus Species 0.000 description 1
- 235000010649 Lupinus albus Nutrition 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010088571 Membrane-Associated Matrix Metalloproteinases Proteins 0.000 description 1
- 102000008887 Membrane-Associated Matrix Metalloproteinases Human genes 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000015624 blood vessel development Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- GKKMCECQQIKAHA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCCCCCCOP(O)(O)=O GKKMCECQQIKAHA-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR99/04875 | 1999-04-19 | ||
| FR9904875A FR2792202B1 (fr) | 1999-04-19 | 1999-04-19 | Extrait peptidique de lupin et composition pharmaceutique ou cosmetique ou nutraceutique comprenant un tel extrait |
| PCT/FR2000/001007 WO2000062789A1 (fr) | 1999-04-19 | 2000-04-18 | Extrait peptidique du lupin et composition pharmaceutique ou cosmetique ou nutraceutique comprenant un tel extrait |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002542199A JP2002542199A (ja) | 2002-12-10 |
| JP2002542199A5 JP2002542199A5 (enExample) | 2013-05-09 |
| JP5329731B2 true JP5329731B2 (ja) | 2013-10-30 |
Family
ID=9544562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000611925A Expired - Fee Related JP5329731B2 (ja) | 1999-04-19 | 2000-04-18 | ルピンのペプチド抽出物およびそれを含有する医薬組成物、化粧品組成物または栄養組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7029713B2 (enExample) |
| EP (1) | EP1171143B9 (enExample) |
| JP (1) | JP5329731B2 (enExample) |
| KR (1) | KR100818010B1 (enExample) |
| AT (1) | ATE279934T1 (enExample) |
| DE (1) | DE60015112T8 (enExample) |
| ES (1) | ES2228500T3 (enExample) |
| FR (1) | FR2792202B1 (enExample) |
| PT (1) | PT1171143E (enExample) |
| WO (1) | WO2000062789A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2813018B1 (fr) * | 2000-08-21 | 2004-02-06 | Boots Co Plc | Compositions cosmetiques renfermant au moins un compose stimulant la neosynthese des laminines, et/ou de l'integrine alpha-2 beta-1 et/ou du collagene iv de la jonction dermo- epidermique |
| FR2823117A1 (fr) * | 2000-11-14 | 2002-10-11 | Pharmascience Lab | Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans |
| FR2823440B1 (fr) * | 2000-11-14 | 2004-06-04 | Pharmascience Lab | Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans |
| FR2822068B1 (fr) * | 2001-03-15 | 2004-12-17 | Pharmascience Lab | Composition topique comprenant une association de lipides furanniques d'avocat et d'isoflavones |
| FR2834216B1 (fr) * | 2001-12-27 | 2004-04-30 | Pharmascience Lab | Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations |
| FR2834213B1 (fr) * | 2001-12-27 | 2004-06-04 | Pharmascience Lab | Composition cosmetique ou pharmaceutique comprenant au moins une alcanolamide pour inhiber la migration des cellules de langerhans, et ses utilisations |
| FR2834638B1 (fr) * | 2002-01-11 | 2004-04-02 | Medix Lab | Composition comprenant en association au moins un flavonoide, au moins un extrait peptidique de lupin et au moins une huile vegetale, son utilisation comme agent dermatologique ou dermo-cosmetique |
| KR100490212B1 (ko) * | 2002-06-21 | 2005-05-17 | 주식회사 바이오랜드 | 피부 각질층의 아미노산 구성비율을 가지는 아미노산복합물과 그것을 함유한 노화방지 화장료 조성물 |
| AU2003264192A1 (en) * | 2002-08-30 | 2004-03-19 | Biopharmacopae Design International Inc. | Plant extracts for treatment of angiogenesis and metastasis |
| EP1405572A1 (en) * | 2002-10-04 | 2004-04-07 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Modified lupin proteins for the preparation of water dispersible product forms of fat soluble compounds |
| FR2847473B1 (fr) | 2002-11-25 | 2007-06-29 | Expanscience Lab | Composition comprenant au moins une oxazolidinone, son utilisation cosmetique et comme medicament |
| FR2856294B1 (fr) | 2003-06-18 | 2005-08-05 | Expanscience Lab | Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite |
| US7740311B2 (en) * | 2004-02-02 | 2010-06-22 | Daihatsu Motor Co., Ltd. | Car seat |
| FR2867074B1 (fr) * | 2004-03-08 | 2009-10-30 | Clarins Lab | Composition cosmetique amincissante comprenant en tant qu'agent actif un inhibiteur de metalloproteinases |
| JP4815752B2 (ja) | 2004-04-01 | 2011-11-16 | 味の素株式会社 | アミノ酸含有飲食品 |
| FR2868703B1 (fr) | 2004-04-08 | 2008-06-13 | Expanscience Sa Lab | Extrait total de lupin constitue d'un extrait de sucres de lupin et d'un extrait peptidique de lupin, procede d'obtention et utilisation |
| FR2869541B1 (fr) | 2004-04-30 | 2007-12-28 | Expanscience Sa Lab | Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee |
| DE102004043802A1 (de) * | 2004-09-08 | 2006-03-09 | Henkel Kgaa | Mund- und Zahnpflege- und reinigungsmittel mit entzündungshemmender Wirkung |
| FR2875134B1 (fr) | 2004-09-16 | 2007-08-24 | Oreal | Utilisation cosmetique d'une composition renfermant un derive ascorbique et des particules de polyamide |
| FR2893628B1 (fr) | 2005-11-18 | 2008-05-16 | Expanscience Laboratoires Sa | Procede d'obtention d'une huile d'avocat raffinee riche en triglycerides et huile susceptible d'etre obtenue par un tel procede |
| KR100849019B1 (ko) * | 2006-06-28 | 2008-07-29 | (주)더페이스샵코리아 | 화이트 루핀 추출물을 함유하는 화장료 조성물 |
| KR101245811B1 (ko) * | 2006-08-18 | 2013-03-20 | 주식회사 엘지생활건강 | 식물 혼합 추출물인 셀리언스를 함유하는 피부노화 예방 및개선용 화장료 조성물 |
| US7571061B2 (en) * | 2007-04-17 | 2009-08-04 | The United States Of America As Represented By The Secretary Of Agriculture | Non-destructive method of measuring a moisture content profile across a hygroexpansive, composite material |
| WO2009042201A1 (en) * | 2007-09-26 | 2009-04-02 | Celgene Cellular Therapeutics | Angiogenic cells from human placental perfusate |
| FR2921836B1 (fr) * | 2007-10-05 | 2013-01-18 | Limousine D Applic Biolog Ditesilab Soc Ind | Utilisation d'un principe actif combinant des principes actifs issus de medicago sativa et de lupinus albus pour lutter contre les poches sous les yeux |
| GB0921001D0 (en) | 2009-11-30 | 2010-01-13 | Aqua Bio Technology Asa | Products and uses |
| AU2011315525B2 (en) | 2010-10-12 | 2016-05-12 | Consumo Em Verde - Biotecnologia Das Plantas, S.A. | Antimicrobial protein |
| FR2975004B1 (fr) * | 2011-05-13 | 2013-06-28 | Expanscience Lab | Nouvel actif anti-rougeurs et compositions cosmetiques le comprenant |
| EP2548458B1 (en) * | 2011-07-22 | 2013-07-03 | HPF Nutraceutics S.r.L. | Lupin-derived compounds having hypotensive activity and process for their production |
| KR101491902B1 (ko) * | 2012-04-06 | 2015-02-11 | 경남과학기술대학교 산학협력단 | 콜라게나제의 활성 저해 효과를 갖는 신규 펩타이드 및 그의 용도 |
| WO2014030950A1 (ko) * | 2012-08-24 | 2014-02-27 | 경상대학교 산학협력단 | 콜라게나제의 활성 저해 효과를 갖는 굴 가수분해물 유래 신규 펩타이드 및 그의 용도 |
| ES2896354T3 (es) | 2012-12-21 | 2022-02-24 | Astellas Inst For Regenerative Medicine | Métodos para la producción de plaquetas a partir de células madre pluripotentes |
| FR3001889B1 (fr) | 2013-02-11 | 2021-02-12 | Expanscience Lab | Utilisation d'une composition comprenant un perseose d'avocat dans la protection des cellules souches epidermiques . |
| EP2961369B1 (en) * | 2013-04-02 | 2018-09-12 | Evonik Schlüchtern GmbH | Compositions of delivery systems and lupine with physical stability |
| FR3011008B1 (fr) | 2013-09-24 | 2017-12-29 | Expanscience Lab | Procedes d'evaluation des effets deleteres des uv sur la peau d'enfant |
| JP6209438B2 (ja) * | 2013-12-19 | 2017-10-04 | 花王株式会社 | 水中油型乳化組成物 |
| FR3023164B1 (fr) * | 2014-07-03 | 2017-10-20 | Expanscience Lab | Extraits peptidiques de lupin et fermete de la peau |
| WO2016051000A1 (es) * | 2014-09-29 | 2016-04-07 | Consejo Superior De Investigaciones Científicas (Csic) | Péptido aislado en un hidrolizado de altramuz y su uso en el tratamiento de enfermedades inflamatorias |
| GB2533379A (en) | 2014-12-18 | 2016-06-22 | Ipco 2012 Ltd | A system and server for receiving transaction requests |
| WO2020192865A1 (en) * | 2019-03-22 | 2020-10-01 | Symrise Ag | Plant peptides and their applications |
| US11951134B2 (en) | 2019-09-30 | 2024-04-09 | North Carolina State University | Cationic platelet lysate compositions and related methods |
| DE102020104279A1 (de) | 2020-02-18 | 2021-08-19 | Gelita Ag | Kollagenhydrolysat als Wirkstoff gegen Parodontitis oder Gingivitis |
| JP7569630B2 (ja) * | 2020-05-25 | 2024-10-18 | 株式会社 資生堂 | 化粧料 |
| WO2025114961A1 (en) * | 2023-11-30 | 2025-06-05 | Universita' Degli Studi Di Milano | Methods to counteract skin aging |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2051017A (en) * | 1932-07-09 | 1936-08-11 | Schwarz | Process for producing from plant materials protein decomposition products, mineral salts, and soluble carbohydrates |
| US2615905A (en) * | 1949-10-31 | 1952-10-28 | Forstmann Walther Geo Heinrich | Recovering valuable components from oil bearing seeds, and products therefrom |
| DE3219245A1 (de) | 1982-05-21 | 1983-11-24 | Mittex Ag | Duengemittel aus lupinen, verfahren zu dessen herstellung und vorrichtung zur durchfuehrung des verfahrens |
| US4402874A (en) * | 1983-01-10 | 1983-09-06 | Thiokol Corporation | Process for the preparation of protein isolates of improved quality from vegetable protein sources using alkali metal borohydrides |
| JP3415198B2 (ja) * | 1993-06-30 | 2003-06-09 | 三省製薬株式会社 | 皮膚外用剤 |
| FR2725130B1 (fr) * | 1994-09-29 | 1996-10-31 | Oreal | Compositions cosmetiques contenant un compose lipidique de type ceramide et un peptide a une chaine grasse, et leurs utilisations |
| PT859553E (pt) * | 1995-10-05 | 2000-10-31 | Finanzconsul Ag | Processo para o tratamento de plantas contendo proteinas |
| FR2739860B1 (fr) * | 1995-10-17 | 1998-01-02 | Coletica | Complexes amphiphiles, procede pour leur preparation et compositions en renfermant |
| JPH107518A (ja) | 1996-06-25 | 1998-01-13 | Ikeda Bussan Kk | 皮膚外用剤 |
| FR2762512B1 (fr) * | 1997-04-24 | 2000-10-13 | Pharmascience Lab | Compositions a base d'huile de lupin, notamment a base d'huile de lupin et d'huile de germe de ble et leur utilisation en cosmetologie, en pharmacie et en tant que complement alimentaire |
| CN1663559B (zh) * | 1998-03-11 | 2010-10-06 | 株式会社创研 | 皮肤健全剂 |
| FR2778565B1 (fr) * | 1998-05-14 | 2000-07-28 | Silab Sa | Procede d'extraction de principes actifs vegetaux a partir de graines de lupin blanc doux, extrait obtenu et composition utilisant au moins une fraction de cet extrait |
| US6630163B1 (en) * | 1999-04-22 | 2003-10-07 | Howard Murad | Method of treating dermatological disorders with fruit extracts |
-
1999
- 1999-04-19 FR FR9904875A patent/FR2792202B1/fr not_active Expired - Lifetime
-
2000
- 2000-04-18 AT AT00920831T patent/ATE279934T1/de not_active IP Right Cessation
- 2000-04-18 JP JP2000611925A patent/JP5329731B2/ja not_active Expired - Fee Related
- 2000-04-18 DE DE60015112T patent/DE60015112T8/de active Active
- 2000-04-18 PT PT00920831T patent/PT1171143E/pt unknown
- 2000-04-18 ES ES00920831T patent/ES2228500T3/es not_active Expired - Lifetime
- 2000-04-18 KR KR1020017013229A patent/KR100818010B1/ko not_active Expired - Fee Related
- 2000-04-18 WO PCT/FR2000/001007 patent/WO2000062789A1/fr not_active Ceased
- 2000-04-18 EP EP00920831A patent/EP1171143B9/fr not_active Expired - Lifetime
-
2003
- 2003-10-03 US US10/678,884 patent/US7029713B2/en not_active Expired - Lifetime
-
2004
- 2004-11-12 US US10/985,988 patent/US7638149B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20040101580A1 (en) | 2004-05-27 |
| JP2002542199A (ja) | 2002-12-10 |
| KR100818010B1 (ko) | 2009-01-28 |
| PT1171143E (pt) | 2005-03-31 |
| US20050148498A1 (en) | 2005-07-07 |
| US7638149B2 (en) | 2009-12-29 |
| EP1171143B1 (fr) | 2004-10-20 |
| KR20020030263A (ko) | 2002-04-24 |
| FR2792202A1 (fr) | 2000-10-20 |
| FR2792202B1 (fr) | 2003-06-13 |
| DE60015112T8 (de) | 2006-08-24 |
| EP1171143B9 (fr) | 2005-03-16 |
| DE60015112T2 (de) | 2006-02-02 |
| ATE279934T1 (de) | 2004-11-15 |
| WO2000062789A1 (fr) | 2000-10-26 |
| DE60015112D1 (de) | 2004-11-25 |
| EP1171143A1 (fr) | 2002-01-16 |
| ES2228500T3 (es) | 2005-04-16 |
| US7029713B2 (en) | 2006-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5329731B2 (ja) | ルピンのペプチド抽出物およびそれを含有する医薬組成物、化粧品組成物または栄養組成物 | |
| US7470438B1 (en) | Ericacea extracts for combating skin aging | |
| JP5588474B2 (ja) | コラーゲンおよび/またはヒアルロン酸産生促進用組成物 | |
| US8722108B2 (en) | Cosmetic and/or pharmaceutical composition comprising an extract of carob as active agent for activating aquaporin expression | |
| US6623769B1 (en) | Administration of lycopene for combating skin/mucous membrane damage | |
| US7838020B2 (en) | Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor | |
| JP4441123B2 (ja) | 加齢皮膚の徴候を処置するための組成物におけるロスマリヌス属の植物抽出物の使用 | |
| US20030152597A1 (en) | Use of at least one sapogenin for prevening the skin or ageing symptoms | |
| JP4689039B2 (ja) | ファゴサイトーシスおよびicam−1発現を調節するための組成物および方法 | |
| FR2755367A1 (fr) | Utilisation d'un extrait de potentille erecta dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie | |
| KR100628413B1 (ko) | 폴리감마글루탐산―비타민c 복합체를 함유하는 콜라게나제저해제 및 그 용도 | |
| US6056944A (en) | Pharmaceutical compositions for oral use including an NSAID and ceramides | |
| JP3280903B2 (ja) | 皮膚外用剤 | |
| JP3936808B2 (ja) | 皮膚刺激性の軽減方法 | |
| KR101668154B1 (ko) | 왕불유행 추출물을 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물 | |
| KR20220072487A (ko) | 지실 당단백 가수분해물을 포함하는 피부 장벽 기능 강화 및 피부 스트레스 완화용 피부 외용제 조성물 | |
| JP2001354582A (ja) | プロテアーゼ阻害剤 | |
| JP2005053797A (ja) | コラーゲン産生促進剤及びコラーゲン架橋形成阻害剤 | |
| US20050065212A1 (en) | Use of at least one 10-hydroxy-2-decenoic acid derivative in compositions for treating the cuteous signs of aging | |
| JP5366358B2 (ja) | 皮膚の老化機構に作用する剤、抗老化用皮膚外用剤、及び抗老化方法 | |
| TWI399209B (zh) | 豬肺萃取物作為基質金屬蛋白酶抑制劑之用途 | |
| KR20170067269A (ko) | 이소바바찰콘을 포함하는 피부 개선용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100622 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100921 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101018 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101025 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101122 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111004 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111222 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120105 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120203 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120210 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120305 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120312 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120405 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130306 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20130306 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130509 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130702 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130725 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |